Actis to infuse over $700 mn to develop life sciences assets

30 Jun 2022 CW Team

Actis is looking to expand its life sciences realty portfolio via its recent acquisition of Rx Propellant and is also looking at inorganic growth via a few more buyouts.

Partner and Head of India and SE Asia Real Estate at Actis, Ashish Singh, told the media that the life sciences sector of India holds huge potential for growth in the current decade, with a large talent pool at competitive cost making it a convincing destination for global research & development (R&D) and manufacturing.

The platform, which leases realty to research & development (R&D) labs and associated facilities of these firms will be developed to over 6 million sq ft from the current 1 million sq ft over the following five years. The company is looking to expand further in Mumbai, Hyderabad, and Bangalore where it already has an existence, and will also add properties in Ahmedabad and Pune.

The firm is planning to grow our operations in the life sciences sector via a buy and build program targeting both greenfield and brownfield assets with a focus on sustainability, Singh said.

He believes India is an evident beneficiary of the manufacturing and supply chains realignment as part of de-risking from China when it comes to the life sciences segment. Patents that currently account for the global market worth about $250 billion, are expiring between 2021 and 2026, and India is placed as a key beneficiary of this unlocking of the market.

India has been attracting a lot of global R&D work in the life sciences industry in the backdrop of an abundant high-quality talent pool and cost savings of around 65% to global corporations.

More outsourcing of this work is likely to push demand for the life sciences-related realty sector while no organised supply of real estate is available for these corporations in India presently as most of it stays fragmented.

Rx Propellant is looking to be a market-leading life science-focused realty developer-operator in India with its long-term partnerships in the Indian contract research organisations ecosystem.

Image Source

Also read: Actis acquires Rs 6,000 cr portfolio of six operating highway projects

A global investor in sustainable infrastructure, Actis is planning to infuse over $700 million to build and develop assets under its platform focused on providing real estate to tenants in the life sciences and related sectors in the country. Actis is looking to expand its life sciences realty portfolio via its recent acquisition of Rx Propellant and is also looking at inorganic growth via a few more buyouts. Partner and Head of India and SE Asia Real Estate at Actis, Ashish Singh, told the media that the life sciences sector of India holds huge potential for growth in the current decade, with a large talent pool at competitive cost making it a convincing destination for global research & development (R&D) and manufacturing. The platform, which leases realty to research & development (R&D) labs and associated facilities of these firms will be developed to over 6 million sq ft from the current 1 million sq ft over the following five years. The company is looking to expand further in Mumbai, Hyderabad, and Bangalore where it already has an existence, and will also add properties in Ahmedabad and Pune. The firm is planning to grow our operations in the life sciences sector via a buy and build program targeting both greenfield and brownfield assets with a focus on sustainability, Singh said. He believes India is an evident beneficiary of the manufacturing and supply chains realignment as part of de-risking from China when it comes to the life sciences segment. Patents that currently account for the global market worth about $250 billion, are expiring between 2021 and 2026, and India is placed as a key beneficiary of this unlocking of the market. India has been attracting a lot of global R&D work in the life sciences industry in the backdrop of an abundant high-quality talent pool and cost savings of around 65% to global corporations. More outsourcing of this work is likely to push demand for the life sciences-related realty sector while no organised supply of real estate is available for these corporations in India presently as most of it stays fragmented. Rx Propellant is looking to be a market-leading life science-focused realty developer-operator in India with its long-term partnerships in the Indian contract research organisations ecosystem. Image Source Also read: Actis acquires Rs 6,000 cr portfolio of six operating highway projects

Infrastructure Transport

19 Dec 2025

Tripura Rail Survey Approved For Jirania–Bodhjung Link

The Ministry of Railways has approved a Final Location Survey (FLS) for a proposed new railway line between Jirania and Bodhjung Nagar in Tripura. The planned section will span 14 km and is estimated to cost around Rs 4.2 million, with the entire alignment located within West Tripura district. The approval marks a key step towards strengthening railway infrastructure and supporting industrial growth in the state. Bodhjung Nagar is Tripura’s principal industrial and commercial hub, developed mainly for resource-based industries such as rubber, bamboo and food processing. The proposed Jirania..

Infrastructure Transport

19 Dec 2025

MCF Raebareli Rolls Out Its 15,000th Passenger Coach

The Modern Coach Factory (MCF) in Raebareli, Uttar Pradesh, has reached a major production milestone with the manufacture of its 15,000th passenger coach on December 15, the Ministry of Railways said. During the current financial year 2025–26, the unit has produced a total of 1,310 coaches so far. Established in 2007 at Lalganj in Raebareli, MCF is among India’s most advanced passenger coach manufacturing facilities. Built at a cost of around Rs 31.92 billion, the factory has an installed annual capacity of 1,000 coaches and is located about 3 km from Lalganj on the Kanpur–Raebareli Roa..

Infrastructure Transport

19 Dec 2025

RVNL Wins Gandak River Rail Bridge Contract

Rail Vikas Nigam Limited (RVNL) has received a Letter of Award from North Eastern Railway for a major railway infrastructure project valued at Rs 1.65 billion. The contract relates to the construction of the substructure for a key railway bridge over the Gandak River. The bridge will be constructed between Paniyahwa and Valmikinagar stations as part of the doubling of the Gorakhpur Cantt–Valmikinagar railway section. Designed to enhance capacity and operational efficiency, the structure will comprise 14 spans of 61 metres each and will be supported by double D-type well foundations. The des..